{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:26:34Z","timestamp":1794324394819,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ER1504A"],"award-info":[{"award-number":["01ER1504A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ER1504B"],"award-info":[{"award-number":["01ER1504B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Juvenile idiopathic arthritis (JIA) is a heterogeneous group of inflammatory joint disorders with a chronic-remitting disease course. Treat-to-target approaches have been proposed but monitoring disease activity and predicting the response to treatment remains challenging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed biomarkers and their relationship to outcome within the first year after JIA diagnosis in the German Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA). CRP, CXCL9, CXCL10, CXCL11, erythrocyte sedimentation rate, G-CSF, IL-6, IL-17A, IL-18, MCP-1, MIP-1\u03b1, MMP-3, S100A8\/A9, S100A12, TNF\u03b1, and TWEAK were measured at baseline and 3\u2009months later.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two-hundred-sixty-six JIA patients with active disease at baseline were included, with oligoarthritis and rheumatoid factor-negative polyarthritis representing the most frequent categories (72.9%). Most biomarkers were elevated in JIA compared to healthy pediatric controls. Patients with systemic JIA had higher CRP, S100A8\/A9 and S100A12 levels compared to other JIA categories. Baseline levels of TWEAK, G-CSF and IL-18 were lower in oligoarthritis patients with disease extension within 1 year. Increased baseline levels of CRP, S100A8\/A9, S100A12 and ESR were associated with the subsequent addition of biologic disease-modifying antirheumatic drugs (DMARDs). Higher baseline ESR, G-CSF, IL-6, IL-17A and TNF levels indicated an increased risk for ongoing disease activity after 12\u2009months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data demonstrate that elevated baseline levels of CRP, S100A8\/A9 and S100A12 as well as increased ESR are associated with the necessity to escalate therapy during the first 12\u2009month of follow-up. Furthermore, biomarkers related to Th17 activation may inform on future disease course in previously treatment-na\u00efve JIA patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00553-x","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:43:03Z","timestamp":1620042183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline"],"prefix":"10.1186","volume":"19","author":[{"given":"Margarita","family":"Ganeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Fuehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Niewerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-3916","authenticated-orcid":false,"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claas H.","family":"Hinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"issue":"2","key":"553_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"8","key":"553_CR2","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/annrheumdis-2016-210511","volume":"76","author":"SJW Shoop-Worrall","year":"2017","unstructured":"Shoop-Worrall SJW, Verstappen SMM, Baildam E, Chieng A, Davidson J, Foster H, et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis. 2017;76(8):1381\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210511.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"553_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","volume":"11","author":"C Hinze","year":"2015","unstructured":"Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11(5):290\u2013300. https:\/\/doi.org\/10.1038\/nrrheum.2014.212.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"553_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366. https:\/\/doi.org\/10.1002\/art.24516.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"553_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139. https:\/\/doi.org\/10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"553_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. Childhood arthritis rheumatology research a, pediatric rheumatology collaborative study G, Paediatric rheumatology international trials O: American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929\u201336. https:\/\/doi.org\/10.1002\/acr.20497.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"553_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/ard.2006.061853","volume":"66","author":"W de Jager","year":"2007","unstructured":"de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66(5):589\u201398. https:\/\/doi.org\/10.1136\/ard.2006.061853.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"553_CR8","first-page":"2359","volume":"21","author":"KL Madson","year":"1994","unstructured":"Madson KL, Moore TL, Lawrence JM 3rd, Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol. 1994;21(12):2359\u201363.","journal-title":"J Rheumatol"},{"issue":"1","key":"553_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","volume":"17","author":"J Anink","year":"2015","unstructured":"Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200. https:\/\/doi.org\/10.1186\/s13075-015-0723-1.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"553_CR10","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. Jama. 2010;303(13):1266\u201373. https:\/\/doi.org\/10.1001\/jama.2010.375.","journal-title":"Jama"},{"issue":"9","key":"553_CR11","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/art.11177","volume":"48","author":"M Frosch","year":"2003","unstructured":"Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2622\u20136. https:\/\/doi.org\/10.1002\/art.11177.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"553_CR12","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"H Wittkowski","year":"2008","unstructured":"Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924\u201331. https:\/\/doi.org\/10.1002\/art.24137.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"553_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/art.40544","volume":"70","author":"C Tappeiner","year":"2018","unstructured":"Tappeiner C, Klotsche J, Sengler C, Niewerth M, Liedmann I, Walscheid K, et al. Risk factors and biomarkers for the occurrence of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis study. Arthritis Rheumatology. 2018;70(10):1685\u201394. https:\/\/doi.org\/10.1002\/art.40544.","journal-title":"Arthritis Rheumatology"},{"issue":"1","key":"553_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, Davi S, Calandra S, Lanni S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatric Rheumatology Online J. 2016;14(1):23. https:\/\/doi.org\/10.1186\/s12969-016-0085-5.","journal-title":"Pediatric Rheumatology Online J"},{"issue":"W1","key":"553_CR15","doi-asserted-by":"publisher","first-page":"W147","DOI":"10.1093\/nar\/gkw419","volume":"44","author":"S Babicki","year":"2016","unstructured":"Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44(W1):W147\u201353. https:\/\/doi.org\/10.1093\/nar\/gkw419.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"553_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/phar.1938","volume":"37","author":"RS Funk","year":"2017","unstructured":"Funk RS, Chan MA, Becker ML. Cytokine biomarkers of disease activity and therapeutic response after initiating methotrexate therapy in patients with juvenile idiopathic arthritis. Pharmacotherapy. 2017;37(6):700\u201311. https:\/\/doi.org\/10.1002\/phar.1938.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"553_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7754\/clin.lab.2013.130734","volume":"60","author":"D Kaminiarczyk-Pyzalka","year":"2014","unstructured":"Kaminiarczyk-Pyzalka D, Adamczak K, Mikos H, Klimecka I, Moczko J, Niedziela M. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA). Clin Lab. 2014;60(9):1481\u201390. https:\/\/doi.org\/10.7754\/clin.lab.2013.130734.","journal-title":"Clin Lab"},{"issue":"3\u20134","key":"553_CR18","first-page":"253","volume":"58","author":"M Spirchez","year":"2012","unstructured":"Spirchez M, Samasca G, Iancu M, Bolba C, Miu N. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab. 2012;58(3\u20134):253\u201360.","journal-title":"Clin Lab"},{"issue":"3","key":"553_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cei.12782","volume":"184","author":"HM Walters","year":"2016","unstructured":"Walters HM, Pan N, Lehman TJ, Adams A, Kalliolias GD, Zhu YS, et al. The impact of disease activity and tumour necrosis factor-alpha inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol. 2016;184(3):308\u201317. https:\/\/doi.org\/10.1111\/cei.12782.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"553_CR20","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-out cohort. Ann Rheum Dis. 2015;74(10):1854\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205372.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"553_CR21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/art.24601","volume":"60","author":"MG Barnes","year":"2009","unstructured":"Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(7):2102\u201312. https:\/\/doi.org\/10.1002\/art.24601.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"553_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/ng.2614","volume":"45","author":"A Hinks","year":"2013","unstructured":"Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013;45(6):664\u20139. https:\/\/doi.org\/10.1038\/ng.2614.","journal-title":"Nat Genet"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fimmu.2019.00450","volume":"10","author":"L Maggi","year":"2019","unstructured":"Maggi L, Mazzoni A, Cimaz R, Liotta F, Annunziato F, Cosmi L. Th17 and Th1 lymphocytes in Oligoarticular juvenile idiopathic arthritis. Front Immunol. 2019;10:450. https:\/\/doi.org\/10.3389\/fimmu.2019.00450.","journal-title":"Front Immunol"},{"issue":"3","key":"553_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/art.23291","volume":"58","author":"K Nistala","year":"2008","unstructured":"Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58(3):875\u201387. https:\/\/doi.org\/10.1002\/art.23291.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"553_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-020-0398-2","volume":"18","author":"N Aljaberi","year":"2020","unstructured":"Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology Online J. 2020;18(1):7. https:\/\/doi.org\/10.1186\/s12969-020-0398-2.","journal-title":"Pediatric Rheumatology Online J"},{"issue":"3","key":"553_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/art.27284","volume":"62","author":"PJ Hunter","year":"2010","unstructured":"Hunter PJ, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62(3):896\u2013907. https:\/\/doi.org\/10.1002\/art.27284.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"553_CR27","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/1529-0131(200008)43:8<1858::AID-ANR23>3.0.CO;2-A","volume":"43","author":"S Guillaume","year":"2000","unstructured":"Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000;43(8):1858\u201365. https:\/\/doi.org\/10.1002\/1529-0131(200008)43:8<1858::AID-ANR23>3.0.CO;2-A.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"553_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","volume":"52","author":"H Moncrieffe","year":"2013","unstructured":"Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology. 2013;52(8):1467\u201376. https:\/\/doi.org\/10.1093\/rheumatology\/ket152.","journal-title":"Rheumatology"},{"issue":"9","key":"553_CR29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"NJ Wilson","year":"2007","unstructured":"Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950\u20137. https:\/\/doi.org\/10.1038\/ni1497.","journal-title":"Nat Immunol"},{"key":"553_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","volume":"55","author":"BE Jones","year":"2018","unstructured":"Jones BE, Maerz MD, Buckner JH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9\u201314. https:\/\/doi.org\/10.1016\/j.coi.2018.09.002.","journal-title":"Curr Opin Immunol"},{"issue":"35","key":"553_CR31","doi-asserted-by":"publisher","first-page":"E3669","DOI":"10.1073\/pnas.1405798111","volume":"111","author":"I Khmaladze","year":"2014","unstructured":"Khmaladze I, Kelkka T, Guerard S, Wing K, Pizzolla A, Saxena A, et al. Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. P Natl Acad Sci USA. 2014;111(35):E3669\u201378. https:\/\/doi.org\/10.1073\/pnas.1405798111.","journal-title":"P Natl Acad Sci USA"},{"issue":"3","key":"553_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/cmi.2010.22","volume":"7","author":"S Leung","year":"2010","unstructured":"Leung S, Liu XB, Fang L, Chen X, Guo T, Zhang JW. The cytokine milieu in the interplay of pathogenic Th1\/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol. 2010;7(3):182\u20139. https:\/\/doi.org\/10.1038\/cmi.2010.22.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"553_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/cmi.2010.21","volume":"7","author":"S Xu","year":"2010","unstructured":"Xu S, Cao XT. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164\u201374. https:\/\/doi.org\/10.1038\/cmi.2010.21.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"553_CR34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/art.40519","volume":"70","author":"SJW Shoop-Worrall","year":"2018","unstructured":"Shoop-Worrall SJW, Verstappen SMM, McDonagh JE, Baildam E, Chieng A, Davidson J, et al. Long-term outcomes following achievement of clinically inactive disease in juvenile idiopathic arthritis: the importance of definition. Arthritis Rheumatology. 2018;70(9):1519\u201329. https:\/\/doi.org\/10.1002\/art.40519.","journal-title":"Arthritis Rheumatology"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00553-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T01:04:44Z","timestamp":1626829484000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00553-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00553-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of the University of Muenster (reference numbers 2010\u2013267-b-S and 2015\u2013670-f-S) and the Charit\u00e9 University Medicine Berlin (reference number EA1\/056\/10). All parents and patients (of 8\u2009years and above) gave their informed consent at study inclusion according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.F. has received research grants and honoraria from Pfizer and Novartis; K.M. is funded by the Rheumastiftung and has received research grants from Pfizer, AbbVie, Roche, and honoraria from AbbVie, Biermann, Chugai, Genzyme, Medac, Roche. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}